Complexity in the treatment of pulmonary large cell neuroendocrine carcinoma

Toshiyuki Kozuki, Nobukazu Fujimoto, Hiroshi Ueoka, Katsuyuki Kiura, Keiichi Fujiwara, Katsuhiko Shiomi, Koichi Mizobuchi, Masahiro Tabata, Shuji Hamazaki, Mitsune Tanimoto

Research output: Contribution to journalArticle

28 Citations (Scopus)

Abstract

Purpose: According to the World Health Organization (WHO) classification of pulmonary large cell neuroendocrine carcinoma (LCNEC), one of the neuroendocrine tumors of the lung, is considered as a variant of non-small cell lung carcinoma. The objective of this study was to investigate the treatment strategy for LCNEC. Methods: We retrospectively reviewed the clinical information of 12 patients with LCNEC. Results: Three patients with stage I disease underwent curative resection but all relapsed within 20 months. One with stage IIA disease underwent non-curative resection received adjuvant chemoradiotherapy (cisplatin plus etoposide) and is well with no evidence of recurrence. Two with stage IIIB disease received concurrent chemoradiotherapy. Both achieved partial response (PR) but relapsed within 2 months. One elderly patient with stage IIIA disease received vinorelbine alone and did not respond. Of five patients with stage IV disease, three received platinum-based chemotherapy but no patient achieved PR. Of five patients with gefitinib as salvage therapy, one achieved PR. Conclusions: The prognosis of LCNEC is poor. To improve the outcome, we must evaluate the effectiveness of adjuvant or neoadjuvant therapy in patients with resectable disease. In addition, the evaluation of systemic and multimodality treatment strategies similar as in small cell lung cancer is worthy of consideration.

Original languageEnglish
Pages (from-to)147-151
Number of pages5
JournalJournal of Cancer Research and Clinical Oncology
Volume131
Issue number3
DOIs
Publication statusPublished - Mar 2005

Fingerprint

Neuroendocrine Carcinoma
Large Cell Carcinoma
Lung
Therapeutics
Adjuvant Chemoradiotherapy
Salvage Therapy
Neoadjuvant Therapy
Neuroendocrine Tumors
Small Cell Lung Carcinoma
Chemoradiotherapy
Etoposide
Platinum
Non-Small Cell Lung Carcinoma
Cisplatin
Recurrence
Drug Therapy

Keywords

  • Chemoradiotherapy
  • Chemotherapy
  • Gefitinib
  • Large cell neuroendocrine carcinoma (LCNEC)
  • Serum tumor marker

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Complexity in the treatment of pulmonary large cell neuroendocrine carcinoma. / Kozuki, Toshiyuki; Fujimoto, Nobukazu; Ueoka, Hiroshi; Kiura, Katsuyuki; Fujiwara, Keiichi; Shiomi, Katsuhiko; Mizobuchi, Koichi; Tabata, Masahiro; Hamazaki, Shuji; Tanimoto, Mitsune.

In: Journal of Cancer Research and Clinical Oncology, Vol. 131, No. 3, 03.2005, p. 147-151.

Research output: Contribution to journalArticle

Kozuki, T, Fujimoto, N, Ueoka, H, Kiura, K, Fujiwara, K, Shiomi, K, Mizobuchi, K, Tabata, M, Hamazaki, S & Tanimoto, M 2005, 'Complexity in the treatment of pulmonary large cell neuroendocrine carcinoma', Journal of Cancer Research and Clinical Oncology, vol. 131, no. 3, pp. 147-151. https://doi.org/10.1007/s00432-004-0626-z
Kozuki, Toshiyuki ; Fujimoto, Nobukazu ; Ueoka, Hiroshi ; Kiura, Katsuyuki ; Fujiwara, Keiichi ; Shiomi, Katsuhiko ; Mizobuchi, Koichi ; Tabata, Masahiro ; Hamazaki, Shuji ; Tanimoto, Mitsune. / Complexity in the treatment of pulmonary large cell neuroendocrine carcinoma. In: Journal of Cancer Research and Clinical Oncology. 2005 ; Vol. 131, No. 3. pp. 147-151.
@article{f1abdadf556b4440a196ff93bf2cb005,
title = "Complexity in the treatment of pulmonary large cell neuroendocrine carcinoma",
abstract = "Purpose: According to the World Health Organization (WHO) classification of pulmonary large cell neuroendocrine carcinoma (LCNEC), one of the neuroendocrine tumors of the lung, is considered as a variant of non-small cell lung carcinoma. The objective of this study was to investigate the treatment strategy for LCNEC. Methods: We retrospectively reviewed the clinical information of 12 patients with LCNEC. Results: Three patients with stage I disease underwent curative resection but all relapsed within 20 months. One with stage IIA disease underwent non-curative resection received adjuvant chemoradiotherapy (cisplatin plus etoposide) and is well with no evidence of recurrence. Two with stage IIIB disease received concurrent chemoradiotherapy. Both achieved partial response (PR) but relapsed within 2 months. One elderly patient with stage IIIA disease received vinorelbine alone and did not respond. Of five patients with stage IV disease, three received platinum-based chemotherapy but no patient achieved PR. Of five patients with gefitinib as salvage therapy, one achieved PR. Conclusions: The prognosis of LCNEC is poor. To improve the outcome, we must evaluate the effectiveness of adjuvant or neoadjuvant therapy in patients with resectable disease. In addition, the evaluation of systemic and multimodality treatment strategies similar as in small cell lung cancer is worthy of consideration.",
keywords = "Chemoradiotherapy, Chemotherapy, Gefitinib, Large cell neuroendocrine carcinoma (LCNEC), Serum tumor marker",
author = "Toshiyuki Kozuki and Nobukazu Fujimoto and Hiroshi Ueoka and Katsuyuki Kiura and Keiichi Fujiwara and Katsuhiko Shiomi and Koichi Mizobuchi and Masahiro Tabata and Shuji Hamazaki and Mitsune Tanimoto",
year = "2005",
month = "3",
doi = "10.1007/s00432-004-0626-z",
language = "English",
volume = "131",
pages = "147--151",
journal = "Journal of Cancer Research and Clinical Oncology",
issn = "0171-5216",
publisher = "Springer Verlag",
number = "3",

}

TY - JOUR

T1 - Complexity in the treatment of pulmonary large cell neuroendocrine carcinoma

AU - Kozuki, Toshiyuki

AU - Fujimoto, Nobukazu

AU - Ueoka, Hiroshi

AU - Kiura, Katsuyuki

AU - Fujiwara, Keiichi

AU - Shiomi, Katsuhiko

AU - Mizobuchi, Koichi

AU - Tabata, Masahiro

AU - Hamazaki, Shuji

AU - Tanimoto, Mitsune

PY - 2005/3

Y1 - 2005/3

N2 - Purpose: According to the World Health Organization (WHO) classification of pulmonary large cell neuroendocrine carcinoma (LCNEC), one of the neuroendocrine tumors of the lung, is considered as a variant of non-small cell lung carcinoma. The objective of this study was to investigate the treatment strategy for LCNEC. Methods: We retrospectively reviewed the clinical information of 12 patients with LCNEC. Results: Three patients with stage I disease underwent curative resection but all relapsed within 20 months. One with stage IIA disease underwent non-curative resection received adjuvant chemoradiotherapy (cisplatin plus etoposide) and is well with no evidence of recurrence. Two with stage IIIB disease received concurrent chemoradiotherapy. Both achieved partial response (PR) but relapsed within 2 months. One elderly patient with stage IIIA disease received vinorelbine alone and did not respond. Of five patients with stage IV disease, three received platinum-based chemotherapy but no patient achieved PR. Of five patients with gefitinib as salvage therapy, one achieved PR. Conclusions: The prognosis of LCNEC is poor. To improve the outcome, we must evaluate the effectiveness of adjuvant or neoadjuvant therapy in patients with resectable disease. In addition, the evaluation of systemic and multimodality treatment strategies similar as in small cell lung cancer is worthy of consideration.

AB - Purpose: According to the World Health Organization (WHO) classification of pulmonary large cell neuroendocrine carcinoma (LCNEC), one of the neuroendocrine tumors of the lung, is considered as a variant of non-small cell lung carcinoma. The objective of this study was to investigate the treatment strategy for LCNEC. Methods: We retrospectively reviewed the clinical information of 12 patients with LCNEC. Results: Three patients with stage I disease underwent curative resection but all relapsed within 20 months. One with stage IIA disease underwent non-curative resection received adjuvant chemoradiotherapy (cisplatin plus etoposide) and is well with no evidence of recurrence. Two with stage IIIB disease received concurrent chemoradiotherapy. Both achieved partial response (PR) but relapsed within 2 months. One elderly patient with stage IIIA disease received vinorelbine alone and did not respond. Of five patients with stage IV disease, three received platinum-based chemotherapy but no patient achieved PR. Of five patients with gefitinib as salvage therapy, one achieved PR. Conclusions: The prognosis of LCNEC is poor. To improve the outcome, we must evaluate the effectiveness of adjuvant or neoadjuvant therapy in patients with resectable disease. In addition, the evaluation of systemic and multimodality treatment strategies similar as in small cell lung cancer is worthy of consideration.

KW - Chemoradiotherapy

KW - Chemotherapy

KW - Gefitinib

KW - Large cell neuroendocrine carcinoma (LCNEC)

KW - Serum tumor marker

UR - http://www.scopus.com/inward/record.url?scp=19944433154&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=19944433154&partnerID=8YFLogxK

U2 - 10.1007/s00432-004-0626-z

DO - 10.1007/s00432-004-0626-z

M3 - Article

C2 - 15538626

AN - SCOPUS:19944433154

VL - 131

SP - 147

EP - 151

JO - Journal of Cancer Research and Clinical Oncology

JF - Journal of Cancer Research and Clinical Oncology

SN - 0171-5216

IS - 3

ER -